All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Brenda Sandmaier, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How safe and efficacious is conditioning with radiolabeled anti-CD45 antibody 211-At-BC8-B10?
How safe and efficacious is conditioning with radiolabeled anti-CD45 antibody 211-At-BC8-B10?
Sandmaier outlines preliminary data from a phase I dose escalation trial that observed conditioning with the radiolabeled anti-CD45 antibody, 211-At-BC8-B10. The study involved patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant. She highlights promising early data for toleration and efficacy of this conditioning regimen.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox